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Background: There was an increasing requirement for novel treatments of osteoarthritis (OA). The aim was to
compare the efficacy of intraarticular Botulinum toxin type A (BoNT-A) and intraarticular hyaluronate plus
rehabilitation exercise in patients with ankle OA.
Methods: This was a prospective, randomized, assessor-blinded study with a 6-month follow-up period, conducted
in the outpatient rehabilitation department at a university-affiliated tertiary care medical center. Seventy-five patients
with symptomatic ankle OA (Kellgren-Lawrence grade 2) were randomized to receive either a single 100-unit
BoNT-A injection into the target ankle (n = 38) or a single hyaluronate injection plus 12 sessions of rehabilitation
exercise (30 minutes/day, 3 times/week for 4 weeks) (n = 37). The primary outcome measure was the Ankle
Osteoarthritis Scale (AOS). Secondary outcome measures included American Orthopedic Foot and Ankle Society
(AOFAS) Ankle/Hindfoot Score, visual analog scale (VAS) for ankle pain, single leg stance test (SLS), Timed
“Up-and-Go” test (TUG), consumption of rescue analgesics and global patient satisfaction.
Results: There were no significant between-group differences in total AOS scores, pain subscale and disability
subscale scores (adjusted mean difference AMD = −0.2, 95% CI = (−0.5, 0.2), p = 0.39; AMD = −0.1, 95% CI = (−0.5, 0.3),
p = 0.57; AMD = −0.2, 95% CI = (−0.6, 0.2), p = 0.36). The 2 groups showed no significant differences in AOFAS, VAS,
SLS, TUG scores and consumption of rescue analgesics at each follow-up visit, except that the hyaluronate group
improved more in SLS than the BoNT-A group at 1-month follow-up. Patients’ satisfaction rate was high, with no
serious adverse events. There was no difference in adverse events between the two groups (p = 1.00).
Conclusions: Treatment with intraarticular BoNT-A or hyaluronate injection plus rehabilitation exercise was associated
with improvements in pain, physical function and balance in patients with ankle OA. These effects were rapid at
2 weeks and might last for at least 6 months. There was no difference in effectiveness between the two interventions.
Trial registration: The trial was registered at clinical trials.gov (Registry number NCT01760577).
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Ankle osteoarthritis (OA) can cause substantial pain
and functional limitations. Symptomatic ankle OA is
found in less than 1% of the adult population and re-
cent research has indicated patients are being diagnosed
with ankle OA with increasing frequency [1,2]. Current
treatment options include analgesics, non-steroidal anti-
inflammatory medication (NSAIDs), weight loss, physical
therapy, exercise, activity modification, assistive devices,
local injections, and surgery. Although many cases can be
treated successfully with surgery, some patients are either
not good candidates for surgery or prefer not to have sur-
gery. Long-term effective and safe alternative treatments
that may reduce pain and improve function yet avoid the
toxic effects of medications should be fully exploited. The
potential treatment options include intraarticular injection
of Botulinum toxin type A (BoNT-A) and hyaluronate in-
jection plus rehabilitation exercise.
BoNT-A has been used clinically for its muscle para-
lyzing effects, but there is increasing evidence to support
using it in pain modulation [3,4]. Recent pilot studies re-
port that BoNT-A injection into painful joints of pa-
tients with various types of arthritis leads to significant
improvement in pain and function and is safe to use
[5-8]. The initial effects for BoNT-A were encouraging
because two thirds of the patients had more than 50%
reduction in pain and was associated with significant
functional improvement [8]. To date, there is no published
literature that has prospectively evaluated the efficacy of
intraarticular BoNT-A in the treatment of ankle OA.
Hyaluronate, a high-molecular-weight polysaccharide
and a major component of the synovial fluid, acts as a
lubricant and shock absorber and helps to maintain the
structural and functional characteristics of the cartilage
matrix. It also inhibits the formation and release of pros-
taglandins, induces proteoglycan aggregation and syn-
thesis, and modulates the inflammatory response [9,10].
There is only limited published literature relating its use
in ankle OA and dosing in the ankles remains an area
for discussion [11-15]. Previous studies showed that 3 or
5 weekly injections of hyaluronate may improve pain
and physical function in patients with ankle OA [11-13].
Theoretically, the ankle joint is much smaller than the
knee, thus it is likely that less hyaluronate is needed to
be effective in the ankle. Exercise has been proven to be
an important factor in maintaining strength and flexibil-
ity and slowing the onset of debilitation in OA [16]. The
advantage of exercise may be its noninvasive nature be-
ing preferred by both the patients and the physicians.
No study to date has examined efficacy of intraarticular
hyaluronate plus rehabilitation exercise in patient with
ankle OA.
There is an increasing requirement for novel treat-
ments of OA as the aging population is expanding withmany patients who are unable to undergo joint surgery.
Effective therapy has been a key therapeutic challenge.
The purpose of this study was to conduct a randomized
controlled trial to compare the efficacy of intraarticular
BoNT-A and intraarticular hyaluronate plus rehabilita-
tion exercise in patients with ankle OA.
Methods
Participants
Patients in this study were referred from our outpatient
orthopedic department with a diagnosis of ankle OA. All
patients fulfilled the following inclusion criteria: (1) an
age of 20–85 years; (2) unilateral ankle pain that had
lasted for at least 6 months, with no significant benefit
from conservative treatment or with an inability to toler-
ate the side effects of medications; (3) ankle radiographs
taken within 6 months equivalent to grade 2 on the
Kellgren-Lawrence grading system [17]; (4) a current total
Ankle Osteoarthritis Scale (AOS) score of (described
below) of >3 and ≤ 9 (possible range, 0–10) [18]; (5) a
normal activity level—i.e., not bedridden or confined to a
wheelchair, and able to walk 30 meters without the aid of
a walker, crutches or cane; and (6) no changes in shoes or
orthotic devices during the study period.
Exclusion criteria included pregnancy or lactation in
women; lower leg trauma other than ankle trauma; pre-
vious surgery involving the spine, hip or knee; presence
of an active joint infections of foot or ankle; history of
rheumatoid arthritis, gout, or any other inflammatory ar-
thropathy, physical therapy involving the affected ankle
within the previous 2 months; surgery involving the af-
fected ankle within the previous twelve months; known
allergy to chicken, egg or BoNT-A; steroid or hyaluro-
nate injections in the ankle within the previous six
months; treatment with anticoagulants or immunosup-
pressives; presence of other comorbidity (such as neo-
plasms, diabetes mellitus or recent trauma) or poor health
status that would interfere with the assessments during
the study.
The medical records for each patient were reviewed,
and the etiology and duration of OA were recorded prior
to the injection. The etiology was determined on the
basis of the medical history, physical examination, and
imaging studies. If no cause could be elucidated, the case
was classified as primary OA.
Study design
This was a prospective, assessor-blinded randomized
controlled trial with a 6-month follow-up period, con-
ducted in the outpatient rehabilitation department at a
university-affiliated tertiary care medical center. The re-
cruitment period was between May 2010 and November
2011. The study was approved by the institutional review
board for human investigation (ethics approval number
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informed consent before being enrolled in the study.
Intake of analgesics or NSAIDs was not permitted dur-
ing the study period. Acetaminophen (500 mg), limited
to 4 g/day was allowed as rescue medication. If the treat-
ment dose was above the stipulated limit (acetamino-
phen 4 g/day), the patient was regarded as a clinical
failure. Patients taking analgesics or NSAIDs stopped
them at least 7 days before the preinjection assessment.
Administration of acetaminophen was stopped at least 8
hours before the follow-up assessments. The administra-
tion of all analgesic medication during the study period
was recorded on a diary card by the patient.
Interventions
After completing the baseline survey within 1 week of
entry into this study, the patients were randomized into
2 groups using block randomization in groups of four by
a study assistant who did not participate in patients’
evaluation or treatment. The BoNT-A group received
intraarticular injection of 100-unit of BoNT-A (Allergan,
Inc, Irvine CA) reconstituted in 2 cc normal saline. The
hyaluronate group received a single injection of 2 ml
sodium hyaluronate (Hyalgan, molecular weight 500-
730 kDa, Fidia Pharmaceutical Corporation, Italy), fol-
lowed by 12 sessions of rehabilitation exercise for 30
minutes/day, 3 times per week for 4 weeks. The exer-
cise program, commencing within 3 days of hyaluronate
injection, included a series of ankle range of motion ex-
ercises, stretching exercises, isometric exercises and
strengthening exercises for ankle muscles, and proprio-
ceptive exercise (Additional file 1). Patients received in-
struction to continue the exercise program done in
hospital at home for 30 minutes/day and a diary card
for exercise was given to improve compliance at home.
The home exercise program was taught by one physical
therapist.
All the injections were performed by a single experi-
enced physician, who took no part in the clinical assess-
ment or in the data analysis. The patient was placed in
the supine position, with the knee flexed and the feet flat
on the plinth. Using aseptic procedures, the ankle joint
was injected by inserting the needle 1 cm anterior to the
distal medial malleolus and advancing the needle poster-
iorly and slightly superiorly toward the middle of the
ankle joint above the talus. If an effusion was present, it
was aspirated before injecting. In this study, the patients
were not blinded to injection material.
Outcome assessments
The clinical assessment was documented by a single as-
sessor blinded to patient groups and intervention. These
tests were conducted pre-injection and at 2 weeks, 1
month, 3 months, and 6 months post injection. Patients’global satisfaction was assessed at 2 weeks, 1 month, 3
months, and 6 months post injection.
Primary outcome measures
The primary outcome measure was the total Ankle Osteo-
arthritis Scale (AOS) score, which is a validated patient-
rated measure including a nine-item pain subscale and a
nine-item disability subscale [18]. The range of possible
scores for the AOS and its subscales is 0 to 10. A score of
0 represents no pain or disability and a score of 10 repre-
sents the worst pain or disability imaginable. The primary
endpoint was 6 months.
Secondary outcome measures
Secondary outcome measures included the following:
(1) American Orthopedic Foot and Ankle Society
(AOFAS) Ankle/Hindfoot Score was a 100-point
scale that devoted 40 points to pain, 50 points to
function and 10 points to alignment [19]. The
maximum score of 100 points denoted no pain and
normal function and alignment.
(2) The patient rated the intensity of average ankle
pain in the previous week using a 10-cm
horizontal visual analog scale (VAS) [20]. The
VAS was marked in 1-cm increments from ‘no
pain’to ‘worst pain’.
(3) Single-leg stance test (SLS) involved raising the
unaffected foot, without touching it to the
affected lower extremity, and maintaining balance
for as long as possible. Each participant
performed three trials, and the best result was
recorded [21].
(4) A Timed “ Up-and-Go” test (TUG) measured
functional mobility and the dynamic balance [22]. A
patient was asked to rise from an armchair, walk 3
meters at a safe and comfortable pace, turn around,
walk back to the chair, and sit down again. The total
time (in seconds) required to complete this series of
tasks was recorded.
(5) Patients rated their level of global satisfaction
relative to the state before the treatment at each
follow-up visit. This rating was based on a 0–6
7-point Likert scale ranging from completely
dissatisfied (0), dissatisfied (1), somewhat dissatisfied
(2), no change (3), somewhat satisfied (4), satisfied
(5) to completely satisfied (6). In analysis, we took
the global satisfaction as a dichotomous variable
with 1 representing satisfied (point 4–6 in the
7-point scale) and 0 representing dissatisfied (point
0–3 in the 7-point scale).
(6) The administration of acetaminophen during the
study period was recorded on a diary card by the
patient.
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recording the occurrence of systemic and local
adverse events on a diary card.
Statistical analysis
Based on the Statistical Software Sample Power 2.0 and
the statistical method used for the study hypothesis (there
was a difference between the efficacy of two interven-
tions), ANCOVA, the required sample size was 35 parti-
cipants for each group (power = 0.8; alpha = 0.05; R2 of
pretest to posttest 0.09; effect size 0.325).
All statistical procedures were conducted with the Sta-
tistical Package for the Social Sciences (version 12.0; SPSS
Inc., Chicago, Illinois). Descriptive statistics such as mean,
standard deviation, frequency and percentage were used
to describe the participants’ demographic data in each
group. Missing data were multiply imputed with regres-
sion methods and five iterations were used that intention-
to-treat analysis can be conducted. The outcome variables
used with multiple imputation included AOS, pain sub-
scale, disability subscale, AOFAS Ankle/Hindfoot Score,
VAS, SLS, TUG, acetaminophen consumption and pa-
tients’ global satisfaction, each at 2 weeks, 1 month, 3
months, and 6 months post injection. The predictor/inde-
pendent variables used were in the following sequence:
group, age, gender, body height, body weight, light or
heavy worker, side of ankle injected, disease duration, and
AOS, pain subscale, disability subscale, AOFAS Ankle/
Hindfoot Score, VAS, SLS, TUG, acetaminophen con-
sumption and patients’ global satisfaction, each at baseline,
2 weeks, 1 month, 3 months, and 6 months post injection.
The analysis of covariance (ANCOVA) using baseline data
as the covariate was used to detect the differences of the
outcome variables (including AOS, AOFAS Ankle/Hind-
foot Score, VAS, SLS, TUG, and analgesics consumption)
between two groups at each post time point. Additionally,
Fisher’s exact test was used to examine if there was signifi-
cant difference in frequency of adverse events/satisfaction
between the two groups. p values of less than 0.05 were
regarded as significant.
Results
Eighty-two patients were initially screened, seven subjects
were excluded as four subjects did not meet inclusion cri-
teria and three met the exclusion criteria. Seventy-five
patients met all eligibility criteria and participated in
the study (Figure 1). Five patients withdrew, two in the
BoNT-A group because of transportation problems and
fear of needle injection, three in the hyaluronate group be-
cause of moving to another city, traffic accident and poor
compliance. Dropout of all these 5 patients occurred prior
to injection treatment. From November 2010 to May
2012, a total of seventy patients completed the study
(attrition rate 6.67%). Among the 75 patients who wereoriginally in the study, ankle OA was attributed to primary
OA in 21 patients. Secondary OA was noted in 54 pa-
tients. Table 1 summarizes the demographic data and pa-
tient characteristics in both groups.
Intention-to-treat analysis
Primary outcome measures
The primary outcome measure was the total AOS. There
were no significant differences between the 2 groups in
total AOS scores, pain subscale and disability subscale
scores (Table 2).
Secondary outcome measures
Table 3 provides a summary of secondary outcome mea-
sures at each follow-up visit. Results of AOFAS Ankle/
Hindfoot Score, VAS, SLS, TUG tests and analgesics
consumption showed no significant differences between
the 2 groups, except that the hyaluronate group im-
proved more in SLS than the BoNT-A group at 1-month
follow-up.
Each of the two treatments resulted in a high rate of
patient satisfaction (94.2% in the BoNT-A group and
94.1% in the hyaluronate group, at least somewhat satis-
fied) at the 6-month follow-up visit (Table 4).
Adverse effects
All patients tolerated the treatment well, with a low inci-
dence of adverse events in both groups. Among the 70
patients who completed this study, transient injection-
site reactions with mild to moderate pain or local swell-
ing was reported by 2 (5.6%) patients in the BoNT-A
group and 2 (5.9%) in the hyaluronate group. No severe
or systemic adverse events were reported during the
study period. There were no significant differences in
adverse events between the two groups (p = 1.00).
Discussion
This prospective study revealed that a single intraar-
ticular injection of BoNT-A and a single hyaluronate
injection plus rehabilitation exercise both resulted in im-
provements in pain, function and balance for patients
with unilateral ankle OA. There were no significant dif-
ferences between the 2 groups in most outcome vari-
ables. In both groups, the patients’ satisfaction rate was
high with no serious adverse events. These effects were
rapid at 2 weeks and could last for at least six months.
This study is the first prospective trial that evaluate effi-
cacy of BoNT-A injection in patients with ankle OA. The
results of using BoNT-A for pain relief in the ankle are
consistent with those of previously studies using BoNT-A
in the joints [5-8]. It is of interest that six months follow-
ing the BoNT-A injections, the mean AOS pain subscale
reduced from 4.5 ± 1.3 to 2.4 ± 1.2, representing an im-
provement of 46.7% from baseline. The mean VAS for






Age (years) 49.5 ± 10.9 50.6 ± 10.3
Male, n (%) 23 (60.5) 23 (62.2)
Weight (kg) 67.5 ± 8.1 67.0 ± 10.5
Height (cm) 166.5 ± 6.5 165.1 ± 8.1
Etiology of OA, secondary OA (%) 27 (71.1) 27(73.0)
Light worker, n (%) 28 (73.7) 27 (73.0)
Side of ankle injected, left, n (%) 13 (34.2) 12 (32.4)
Disease duration (years) 5.6 ± 3.7 5.3 ± 4.0
Total AOS 4.9 ± 1.5 4.7 ± 1.0
Pain subscale 4.5 ± 1.3 4.5 ± 1.1
Disability subscale 5.2 ± 1.9 5.0 ± 1.3
Data are mean ± standard deviation or number (percentage).
BoNT-A = Botulinum toxin type A; HA = Hyaluronate; OA = Osteoarthritis;
AOS = Ankle Osteoarthritis Scale.
Figure 1 Flow diagram of patients through the trial.
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an improvement of 55.0%. Achieving this degree of pain
reduction appears to be clinically relevant, since reduc-
tions in chronic pain intensity of at least 30% have been
reported to reflect at least moderate clinically important
changes [23]. The result of our study is very encouraging,
as it continues to build on the existing data suggesting
benefits from BoNT-A injections in the joints.
The exact mode of action of BoNT-A in OA has not
been revealed completely. OA represents a complexity
of pain conditions, including manifestations of both no-
ciceptive and neuropathic mechanisms driven by joint
pathophysiology and abnormal excitability in peripheral
and central pain pathways [24-29]. The peripheral and
central sensitizations may amplify the joint pain. It has
been suggested that BoNT-A suppresses the secretion of
neurotransmitters directly decreasing peripheral sensitiza-
tion and indirectly decreasing central sensitization [30,31].
Recent studies also indicated a potential for inhibiting
the release of mediators involved in nociception such
Table 2 Summary of primary outcome measures by data of multiple imputation
Outcome Baseline 2 weeks 1 month 3 months 6 months
BoNT-A HA BoNT-A HA BoNT-A HA BoNT-A HA BoNT-A HA
Total AOSa 4.9 ± 1.5 4.7 ± 1.0 2.7 ± 1.3 3.0 ± 1.3 2.5 ± 1.4 2.6 ± 1.2 2.5 ± 1.4 2.6 ± 1.2 2.6 ± 1.2 2.7 ± 1.0
A.M.D. (95% CI) −0.3 (−0.8, 0.2) −0.2 (−0.5, 0.2) −0.2 (−0.6, 0.2) −0.2 (−0.5, 0.2)
pb 0.18 0.41 0.30 0.39
Pain subscalea 4.5 ± 1.3 4.5 ± 1.1 2.5 ± 1.2 2.8 ± 1.3 2.3 ± 1.4 2.3 ± 1.0 2.3 ± 1.4 2.4 ± 1.1 2.4 ± 1.2 2.5 ± 1.1
A.M.D. (95% CI) −0.3 (−0.8, 0.2) −0.04 (−0.4, 0.3) −0.2 (−0.6, 0.2) −0.1 (−0.5, 0.3)
pb 0.24 0.85 0.42 0.57
Disability subscalea 5.2 ± 1.9 5.0 ± 1.3 3.0 ± 1.5 3.2 ± 1.4 2.8 ± 1.5 2.9 ± 1.7 2.8 ± 1.5 2.8 ± 1.4 2.9 ± 1.3 2.9 ± 1.1
A.M.D. (95% CI) −0.3 (−0.8, 0.2) −0.3 (−0.7, 0.2) −0.2 (−0.7, 0.2) −0.2 (−0.6, 0.2)
pb 0.18 0.23 0.31 0.36
NOTE: Values are the mean ± standard deviation; BoNT-A = Botulinum toxin type A; HA = Hyaluronate; AOS = Ankle Osteoarthritis Scale; A.M.D. = Adjusted mean
difference; CI = Confidence interval.
aHigher scores represent worse pain or function.
bANCOVA for comparing two groups in each posttest.
The primary endpoint was 6 months.
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glutamate, which leads to a decrease in pain transmis-
sion and peripheral sensitization [32].
To our knowledge, this is also the first study that eval-
uate efficacy of a single hyaluronate injection plus reha-
bilitation exercise in patients with ankle OA. The mean
AOS pain subscale reduced from 4.5 ± 1.1 to 2.5 ± 1.1 at
6-month follow-up, corresponding to an improvement ofTable 3 Summary of secondary outcome measures by data of
Outcome Baseline 2 weeks
BoNT-A HA BoNT-A HA Bo
AOFAS Ankle/
Hindfoot score
71.3 ± 11.6 70.0 ± 11.7 84.5 ± 8.8 82.9 ± 12.3 88.1
A.M.D. (95% CI) 1.4 (−2.5, 5.4)
pb 0.48
VAS pain scalea 4.0 ± 1.8 3.9 ± 1.2 1.8 ± 1.2 1.8 ± 1.2 1.8
A.M.D. (95% CI) −0.04 (−0.5, 0.5)
pb 0.88
SLS 25.0 ± 19.4 25.4 ± 16.0 34.1 ± 26.6 36.8 ± 22.5 36.9
A.M.D. (95% CI) −2.3 (−6.3, 1.7)
pb 0.26
TUGa 8.4 ± 3.0 8.2 ± 2.5 7.2 ± 2.3 6.9 ± 2.4 6.5




16.0 ± 5.4 17.0 ± 6.4 8.4 ± 5.2 8.9 ± 4.9 8.3
A.M.D. (95% CI) −0.1 (−1.6, 1.5)
pb 0.93
Values are the mean ± standard deviation; AOFAS = the American Orthopedic Foot a
TUG = timed “Up-and-Go” test; The possible range for the AOFAS score was 0–100;
difference; CI = Confidence interval.
aHigher scores represent worse pain or function.; bANCOVA for comparing two grou
*p < 0.05.44.4% from baseline. The mean VAS for ankle pain re-
duced from 3.9 ± 1.2 to 1.7 ± 1.1, representing an improve-
ment of 56.4%. Achieving this degree of pain reduction
suggests a success in chronic pain clinical trials, using the
same criteria that pain reductions of at least 30% appear
to reflect at least moderate clinically important changes
[23]. We previously reported a mean AOS score reduction
from 5.5 ± 2.1 prior to injection to 3.2 ± 1.9 points at sixmultiple imputation
1 month 3 months 6 months
NT-A HA BoNT-A HA BoNT-A HA
± 12.1 88.1 ± 11.8 89.0 ± 7.3 88.1 ± 11.3 88.3 ± 7.2 86.4 ± 12.5
−0.2 (−4.1, 3.8) 0.8 (−2.8, 4.4) 1.9 (−1.7, 5.5)
0.93 0.66 0.30
± 1.3 1.7 ± 1.5 1.7 ± 1.2 1.7 ± 1.1 1.8 ± 0.9 1.7 ± 1.1
0.01 (−0.6, 0.6) 0.01 (−0.4, 0.5) 0.1 (−0.3, 0.5)
0.97 0.95 0.71
± 23.8 43.0 ± 18.6 36.8 ± 21.8 41.7 ± 19.6 36.5 ± 23.3 40.0 ± 20.0
−5.7 (−10.4, -1.0) −4.6 (−9.7, 0.5) −3.1 (−8.2, 2.1)
0.02* 0.08 0.24
± 1.7 6.3 ± 1.9 6.6 ± 1.7 6.6 ± 2.0 6.8 ± 1.8 6.7 ± 2.1
0.1 (−0.4, 0.5) −0.1 (−0.6, 0.4) −0.04 (−0.5, 0.5)
0.72 0.56 0.88
± 4.3 8.5 ± 3.2 8.7 ± 4.9 9.3 ± 3.6 9.2 ± 4.9 9.5 ± 6.0
0.3 (−1.0, 1.5) −0.1 (−1.5, 1.4) 0.3 (−1.1, 1.7)
0.67 0.94 0.66
nd Ankle Society, VAS = Visual analog scale; SLS = single leg stance test;
BoNT-A = Botulinum toxin type A; HA = Hyaluronate; A.M.D. = Adjusted mean
ps in each posttest.
Table 4 Satisfaction for the treatment of ankle osteoarthritis by data of multiple imputation
Satisfieda Dissatisfiedb Comparison between groups
BoNT-A HA BoNT-A HA pc OR (95% CI)
2 weeks 34.4 (90.5) 33.4 (90.3) 3.6 (9.5) 3.6 (9.7) 1.00 1.03 (0.2, 4.7)
1 month 35.2 (92.6) 34.4 (93.0) 2.8 (7.4) 2.6 (7.0) 1.00 0.87 (0.1, 6.6)
3 months 38.0 (100.0) 37.0 (100.0) 0.0 (0.0) 0.0 (0.0) - -
6 months 35.8 (94.2) 34.8 (94.1) 2.2 (5.8) 2.2 (5.9) 1.00 1.08 (0.2, 7.4)
aSatisfied including somewhat satisfied, satisfied, and completely satisfied.
bDissatisfied including completely dissatisfied, dissatisfied, somewhat dissatisfied, and no change.
cFisher’s exact test.
Data are number (percentage).
BoNT-A = Botulinum toxin type A; HA = Hyaluronate; OR = Odds ratio; CI = Confidence interval.
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tients with Kellgren-Lawrence grade 2 or 3 ankle OA [13].
In another pilot study, we reported a mean AOS score re-
duction from 5.1 ± 1.9 to 2.4 ± 1.9 at the 6-month follow-
up visit after five weekly injections of another hyaluronate
formulation (ARTZ; Seikagaku Corporation, Japan) in pa-
tients with Kellgren-Lawrence grade 1 or 2 ankle OA [12].
Although pain and disability reduction was also docu-
mented in our current study, the results were difficult to
compare with previous studies because of differences in
the formulation, the number of injections, the radiogra-
phic severity, and the study design. In our current study, a
single hyaluronate injection, offering similar clinical effi-
cacy, allows a major compliance and convenience from
the patients and reduces risks connected to intraarticular
injection. This novel therapy seems promising and the
optimal dose of hyaluronate and duration of rehabi-
litation exercise await further investigation. However,
two treatments applied to the same group of patients,
the improvement could have been due just to the re-
habilitation component.
Balance is an important component of performance
for transfer, ambulatory tasks and many daily activities.
To date, there was only one case series that examine the
effect of hyaluronate injections for ankle OA on balance
[13]. Hubbard et al. reported significant impairments in
mechanical and sensorimotor function in patients with
ankle OA [33]. Pain associated with OA frequently leads
to a reduced activity level and weakening of muscles,
resulting in a secondary increase in instability. Reduced
muscle strength and deficits in lower limb propriocep-
tion associated with OA could compromise effective and
timely motor responses for maintaining balance [34,35].
In this study, we demonstrated that the two novel the-
rapies are associated with improvement in pain and
disability, as well as improvement in balance function.
Although the mechanisms with balance improvement
remain unknown, we believe that pain reduction might
be one of the major contributing factors. Interestingly,
the hyaluronate group improved more in SLS than theBoNT-A group at 1-month follow-up. We thought that
the improvement could have been due to the rehabilita-
tion component in the hyaluronate group.
This pilot study supports that a single injection of
BoNT-A or one hyaluronate injection plus rehabilitation
exercise may be valuable and attractive treatment option
for ankle OA, especially when surgery is contraindicated
or deferred due to age, comorbidities, or patient prefer-
ence. The positive effects of the two therapeutic options
in patients with ankle OA suggest that both are promis-
ing approaches worthy of serious clinical investigation.
Several limitations existed in this study. We recruited
patients with Kellgren-Lawrence grade 2 ankle OA only,
the results can not be generalized to other OA popula-
tions with different radiographic severity. The six-month
trial period was relatively short, it is unclear how much
longer the clinical benefits would have been maintained.
We acknowledged that the hyaluronate group in our
study received rehabilitation and the BoNT-A group did
not, this may threaten the internal validity of the study.
Due to economic and manpower concerns, we did not
have sham control group (saline injection), sham injec-
tion plus rehabilitation group, or rehabilitation exercise
only group. The improvements could be attributed to
intraarticular injection, rehabilitation, non-intervention
effects such as placebo or synergic effects of both treat-
ments. It is difficult to address the relative contribution
of each therapy procedure to the functional gains. This
remained an interesting point important for further in-
vestigation. Further studies comparing BoNT-A injection
with corticosteroid injections, different molecular weight
hyaluronate, NSAIDs, or therapeutic exercise, as well
as other potential combination therapy, may help de-
termine the best overall treatment plan for patients
with ankle OA. The cost-benefit ratio should be ana-
lyzed also.
Conclusions
This study shows that both treatments with a single
BoNT-A injection to the ankle joint or a single hyaluronate
Sun et al. Journal of Foot and Ankle Research 2014, 7:9 Page 8 of 9
http://www.jfootankleres.com/content/7/1/9injection plus rehabilitation exercise were associated with
improvements in pain, function and balance in patients
with unilateral ankle OA. There were no significant dif-
ferences in effectiveness between the 2 treatment groups.
These effects are rapid at 2 weeks and can last for at least
6 months.
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